key: cord-0983124-iea4x1qg authors: Wagner, Ralf; Meißner, Juliane; Grabski, Elena; Sun, Yuansheng; Vieths, Stefan; Hildt, Eberhard title: Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID‐19 vaccines in Europe date: 2021-05-21 journal: Allergy DOI: 10.1111/all.14868 sha: eec0d3453eb9417ab5de8ee420476e479d395c83 doc_id: 983124 cord_uid: iea4x1qg The ongoing COVID‐19 pandemic caused by the SARS‐CoV‐2 coronavirus has affected the health of tens of millions of people worldwide. In particular, in elderly and frail individuals the infection can lead to severe disease and even fatal outcomes. Although the pandemic is primarily a human health crisis its consequences are much broader with a tremendous impact on global economics and social systems. Vaccines are considered the most powerful measure to fight the pandemic and protect people from COVID‐19. Based on the concerted activities of scientists, manufacturers and regulators, the urgent need for effective countermeasures has provoked the development and licensure of novel COVID‐19 vaccines in an unprecedentedly fast and flexible manner within <1 year. To ensure the safety and efficacy of these novel vaccines during the clinical development and the routine use in post‐licensure vaccination campaigns existing regulatory requirements and procedures had to be wisely and carefully adapted to allow for an expedited evaluation without compromising the thoroughness of the regulatory and scientific assessment. In this review, we describe the regulatory procedures, concepts and requirements applied to guide and promote the highly accelerated development and licensure of safe and efficacious COVID‐19 vaccines in Europe. range of symptoms of COVID-19 have been reported, ranging from asymptomatic and mild respiratory disease to severe illness and hospitalization or even fatal outcome. Typical symptoms are, for example, fever or chills, cough, shortness of breath, fatigue, headaches, loss of taste or smell, nausea or vomiting, and diarrhoea. 4 Elderly people and people who have existing underlying medical conditions, like heart or lung diseases or diabetes, are at higher risk for developing more serious complications due to a SARS-CoV-2 infection. Another group of people, which faces higher risks to be infected, are healthcare professionals. As of April 12, 2021, four COVID-19 vaccines have been granted a conditional marketing authorization (CMA) in the EU and three other vaccine candidates are under regulatory review at the EMA (Table 1) . According to the EU legislation, a CMA can be issued for vaccines in emergency situations in response to public health threats. A CMA is a valuable option to expedite vaccine licensure without undue depletion of data requirements. 5 The granting of a CMA is based on the reliable demonstration of a positive benefit-risk-balance at the time of licensure under the precondition that additional data need to be provided post-marketing in fulfilment of defined specific obligations. [6] [7] [8] CMAs have been granted before for other vaccines such as pandemic influenza and Ebola vaccines but also for a wide range of novel therapeutics(listed in 9 ). Globally, numerous other vaccine candidates are presently in development and in different stages of clinical exploration. 10 In the EU, new innovative vaccines are commonly licensed via the centralized procedure operated by the European Medicines Agency (EMA), whereby the vaccine is approved in all EU states including Norway, Iceland and Lichtenstein. As laid down in the respective legislation, 11,12 a centralized procedure is mandatory when the medicinal product, for example, a vaccine, is produced by using recombinant DNA technology, includes a totally new active pharmaceutical substance or if it is intended to be used for specific innovative indications which have not been granted before in the EU. The evaluation process for granting a centralized marketing authorization is a formally established procedure with predetermined timelines and highly defined regulatory requirements concerning all essential aspects relevant for vaccine licensure. From a procedural point of view, the evaluation process, conducted at the regulatory authorities together with EMA, formally encompasses a total of 210 days. 13 This includes the in-depth assessment performed by two national agencies assigned as rapporteurs, the consideration and inclusion of comments into the assessment reports received by the EU concerned member states (CMS) as well as all discussions of specific aspects in EMA working groups. At certain time points within this procedure, the applicant has the opportunity to respond and resolve open issues identified by the rapporteurs during their It is easily understood that the above described procedural timelines had to be drastically accelerated to become applicable for the licensure of the COVID-19 vaccine in an emergency situation. In addition to the dramatic reduction of the actual processing time for data evaluation achieved by highly shortened and ambitious procedural timelines, the regulatory assessment was further expedited by applying a 'rolling review' approach at the EMA ( Figure 1 ). This allows a very flexible and time-optimized processing and assess- Form and content of the documentation to be submitted for licensure are defined by the requirements of the common technical dossier structure (CTD) that is applied also in other regulatory environments such as the United States and Japan. The scientific evaluation for regulatory approval is based on three major sources of vaccine-related characteristics that comprise quality aspects as well as the non-clinical and clinical evaluation that are contained in CTD modules 3, 4 and 5, respectively. CTD modules 1 and 2 contain administrative information and summaries of modules 3-5, respectively. In its entirety, the quality-related documentation submitted in CTD module 3 shall assure the consistency of the manufacturing process and the resulting final vaccine product. Consequently, information from many different quality-related areas such as the pharmaceutical composition, characteristics and usage of starting materials, development and conduct of the manufacturing process, GMP-compliance, 14 in-process controls and specifications, methods applied and aspects of microbial safety are of key importance F I G U R E 1 Schematic outline of the rolling review (RR) procedure. In the RR discrete data packages are submitted for regulatory evaluation immediate upon their availability. In this way, the time before the official submission of the marketing authorization application (MAA) can be spent for regulatory evaluation. Normally, as soon as the MAA is submitted the CHMP opinion and the EC decision can be granted within several days. For more details please see the description in the text to enable a sound regulatory evaluation ( Table 2) . Only based on the keen and comprehensive knowledge and control of all these crucial aspects along with the appropriate release testing scheme, the consistent and intended quality of every single vaccine batch produced after licensure can be guaranteed. In this context, it is important to bear in mind that in contrast to chemically-defined medicines vaccines are highly complex biological products that cannot be sufficiently characterized solely on the basis of physicochemical properties. To enable a rapid and considerably accelerated start of the clin- Compliance with all key quality requirements is considered a fundamental prerequisite also for the licensure of COVID-19 vaccines in a pandemic situation. Yet, it is clear that due to the highly accelerated manufacturing development of these vaccines certain qualityrelated information will not be as comprehensive and conclusive as for common vaccines prior to licensure. This affects the number and characteristics of large-scale batches produced, implemented in-process controls and specifications, as well as stability data that might all need to be adjusted or narrowed in the post-licensure period in response to production data achieved during commercial manufacture. Therefore, certain outstanding issues identified during the regulatory evaluation are being classified formally as 'specific obligations' or 'recommendations' that have to be resolved by the manufacturer post-licensure following a fixed predetermined time table. The application of platform technologies is recommended so that pertinent quality characteristics and manufacturing experiences for similar non-COVID-19 vaccines can be applied as supportive data in order to gain broader insight into the novel vaccine under review. In any case, the quality documentation presented at the time of licensure must be appropriate to clearly conclude that the established manufacturing process and the dedicated control scheme will consistently yield COVID-19 vaccine batches of the intended and TA B L E 2 Overview to general quality-related regulatory requirements for human vaccines and COVID-19 specific quality aspects • Detailed information about chemical composition (nature, quality and quantity) • Description of production process Process steps and intermediates Elements of process control The primary objective of the non-clinical testing programme is to examine vaccine-specific tolerability, immunogenicity and efficacy in animal models prior to entering into human clinical trials. 16 showed that ERD is presumably the consequence of immunization with antigens that are not properly processed or in the non-native confirmation due to chemical inactivation with agents such as formalin. The resulting non-protective antibody response to these non- trials for novel vaccines can be a challenging and risk-prone step that needs to be solidly controlled and regulated. 33 Another To cope with this extraordinary urgency, evaluation times for clinical trial approvals at the responsible authorities were drastically re- sequentially in a staggered mode to ensure that the preceding vaccine recipient was monitored for any potential safety signal for at least 24 hours before the next subject was vaccinated. Immediately upon their availability data from this FIH trial were assessed by the responsible regulatory agency to decide whether the progression into the following clinical stage (phase Ib or IIa) could be granted without the need for another separate clinical trial application. In phase Ib/ IIa, the study population was expanded to include elderly subjects (>60 yoa) and participants with certain comorbidities or pre-exposed to SARS-CoV-2. As for the initial phase I study, endpoints were primarily safety-related and further directed towards the characteriza- Another important topic from a regulatory perspective is the monitored and determination of the long-term efficacy and safety of the licensed COVID-19 vaccines. As described above, the available vaccines have been developed and licensed under highly accelerated conditions. Therefore, at present only very little is known about the safety and efficacy of the vaccines currently used in large vaccination campaigns. It will hence be essential to collect data on the long-term efficacy from the continued clinical trials as well as the post-licensure field effectiveness studies currently being initiated. Further, a more comprehensive insight into the safety and tolerability profile of the vaccines will be gained from routine pharmacovigilance monitoring and from pertinent safety studies conducted globally. 61 For COVID-19 vaccines to be administered to children and adolescents a paediatric investigational plan is required to be filed to EMA covering all paediatric age groups, including neonates. 62 66 or are expected to become available shortly for the vaccines produced by Moderna and Janssen. It seems reasonable to assume that these data will pave the way for the approval of paediatric indications for these vaccines in the near or medium-term future. Overview of lethal human coronaviruses SARS and MERS: recent insights into emerging coronaviruses Vaccine confidence in the time of COVID-19 Regulatory: Conditional Marketing Authorisation COVID-19 Vaccine AstraZeneca COVID-19 Vaccine The Netherlands: EMA /83/EC on the Community Code Relating to Medicinal Products for Human Use of the European Parliament and of the Council. Brussels, Belgium and Community Procedures for the Authorisation and Supervision of Medical Products for Human and Veterinary Use and Establishing a European Medicines Agency of the European Parliament and of the Council marke ting-autho risat ion/pre-autho risat ionguida nce#5.1-proce dure-section Commission directive 2003/94/EC. laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use Regulation of the European Parliament and of the Council on the Conduct of Clinical Trials with and Supply of Medicinal Products for Human Use Containing or Consisting of Genetically Modified Organisms Intended to Treat or Prevent Coronavirus Disease P31-63.pdf?ua=1. Accessed March 1, 2021. 17. Directive 2004/9/EC of the European Parliament and of the Council. on the inspection and verification of good laboratory practice (GLP) Antibody-dependent enhancement of coronavirus Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccines Immunother Enhancement of the infectivity of arboviruses by specific Antisera produced in domestic fowls Fc receptors in antibody-dependent enhancement of viral infections Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications Viral-induced enhanced disease illness Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine Brief history and characterization of enhanced respiratory syncytial virus disease Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern First-in-human clinical trials with vaccines-what regulators want First %20reg ulato ry%20 COV ID-19%20wor kshop %20-%20mee ting%20rep ort_March %202020.pdf. Accessed ICMRA. ICMRA SARS-CoV-2 Vaccines Workshop. Kandlakoya, India: ICMRA; 2020 scien tific -guide line/guide line-strat egies -ident ify-mitig ate-risks -first -human -early -clini cal-trial s-inves tigat ional_en Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2 Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development Animal models for COVID-19 Pathogenesis and transmission of SARS-CoV-2 in golden hamsters Directive 2001/20/EC of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use Regulation on clinical trials on medicinal products for human use, and repealing Directive Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia A novel coronavirus from patients with pneumonia in China Investigation of Novel SARS-CoV-2 Variant. Variant of Concern 202012/01, Technical Briefing 2. London, UK: Public Health England Switzerland: WHO Risk Related to the Spread of New SARS-CoV-2 Variants of Concern in the EU/EEA -First Update. Solna Municipality, Sweden: ECDC Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition SARS-CoV-2 evolution and vaccines: cause for concern. The Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv: the preprint server Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. bioRxiv : the preprint server Emergence and rapid spread of a new severe acute respiratory syndromerelated coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Reflection Paper on the Regulatory Requirements for Vaccines Intended to Provide Protection Against Variant Strain(s) of SARS-CoV-2. Amsterdam, The Netherlands: EMA Plan of the EU Regulatory Network for COVID-19 Vaccines. EMA/333964/2020. Amsterdam, The Netherlands: EMA EMA. Paediatric Investigation Plans EMA. Paediatric Investigation Plan: BNT16b2. BioNTech/Pfizer decis ion-5-janua ry-2021-agree mentpaedi atric -inves tigat ion-plan-grant ing-defer ral-covid -19_en.pdf decis ion-30-novem ber-2020-agree mentpaedi atric -inves tigat ion-plan-grant ing-defer ral-mrna_en Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals Regulatory: COVID-19 Vaccines Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe